Board Of Directors
Chairman Of The Board
Craig Jones serves as the Chairman at eStudySite. He is also Chairman and CEO of InnoCentive, on the Board of Directors of Construction Software Technologies and Chairman of the Board of National Research Institute.
He is a 30-year veteran of the venture capital and private equity industry and has served as Chairman and Board member of many successful software and healthcare companies. Mr. Jones was most recently on the Board of Advisors and the first institutional investor of HealthDataInsights (sold to HMS Holdings for $400 million) and on the Board of Directors of TC3 Health (sold to Emdeon for over $100 million).
He has invested extensively in over 50 innovative companies, including those in the healthcare IT, healthcare services, SaaS, and internet sectors. For the past several years, Mr. Jones has been angel investing in later stage secondary positions in companies such as LinkedIn, Facebook, Twitter, and eHarmony.com.
Mr. Jones is the founding Managing Partner of Ticonderoga Capital where recent software investment successes include AFS Technologies (sold to Goldman Sachs) and IRTH (sold to Crane Group). Mr. Jones has overseen investments of over $400 million in his private equity career. Previously, he was a Managing Director at Dillon, Read & Co. and head of its venture capital partnerships, a Vice President at Advent International, an associate at Centennial Ventures, and a management consultant with Bain & Co. Mr. Jones is a graduate Magna Cum Laude of Harvard Law School.
Tom Wardle serves as the President and Chief Executive Officer. In this role he leads and executes the strategy of eStudySite. Tom has a diverse background with more than 32 years of progressive responsibility in pharmaceutical R&D and healthcare, with 28 years in pharmaceutical research. In his last position Tom was the Chief Operating Officer of Worldwide Clinical Trials (WCT), a full service, phase I-IV global contract research organization with operations in more than 40 countries. Tom was a key senior management team member who founded WCT in 2007. The company initially organized through mergers of several CROs and then subsequently grew from 450 employees to 1400 employees. From 1997 to 2007, Tom held executive management positions at two other global contract research organizations. From 1988 to 1997 Tom was the operations manager at California Clinical Trials which was one of the largest Phase I–III clinical pharmacology and investigational sites in the U.S. During this period Tom directly conducted or supervised more than 300 protocols in CNS, Cardiovascular, Infectious Disease, and Metabolic indications. Tom has an undergraduate degree in Exercise Physiology from BYU, a Master of Science in Kinesiology from UCLA and a Master of Business Administration (Finance) from Rutgers University.
Mark R. Benham
Mr. Benham has eighteen years of experience in private equity and venture capital. Prior to co-founding Celerity Partners and serving as Managing Partner, from 1988-1992 he was a Senior Investment Officer of Citicorp Venture Capital, Ltd. in New York. Prior to joining Citicorp, Mr. Benham served as the U.S advisor of Yamaichi UniVen Co., Ltd, the venture capital unit of Yamaichi Securities International. Mr. Benham holds a B.A. from the University of California, Berkeley, and an M.A. and M.B.A. from The University of Chicago, both with honors. Mr. Benham is a director of Nu Visions, Verari Systems, O Premium Waters, Rincon Industries and Peer 1 Network.
Matthew R. Kraus
Matthew Kraus is currently a partner at Celerity. Prior to joining Celerity, Mr. Kraus was a Managing Director and Founder of Harvey & Company, a merchant bank based in Irvine, CA. While at Harvey & Company, he conceived, developed and executed numerous acquisition strategies. Previously, Mr. Kraus was an analyst at W.E. Myers & Company, a merchant bank. Mr. Kraus received a B.A in Political Science from Bucknell University. He is a director of several private companies.
David McCarthy, Jr
Dave McCarthy is the President of D.R. McCarthy & Associates, Inc., a management consulting firm working with start-up and middle market companies and their investors. He acted as interim Chief Operating Officer of eStudySite for an extended period during 2007, and has served on the Company’s Board of Directors since that time. While at Bain & Company he spent several years consulting in hospitals implementing value improvement and best practice methodologies for the delivery of clinical services. Mr. McCarthy has worked with Private Equity and Venture Capital interests in number of portfolio companies, and founded a successful software company that was sold to Oracle Corporation. Early in his career, he worked in the Corporate Finance Department of the First Boston Corporation. He holds an A.B. degree with honors from Princeton University, and an M.B.A. from Stanford University.
William O'Riordan, M.D.
Chief Medical Officer, Medical Division
Dr. William O’Riordan, Chief Medical Officer, founded eStudySite in 1999 along with twelve healthcare providers with whom he’d performed research for over ten years. Dr. O’Riordan has been involved in emergency medicine for more than thirty years at St. Francis Medical Center, Paradise Valley Hospital and Sharp Chula Vista Medical Center. His academic appointments include Harbor General Hospital–UCLA Medical Center and UCSD. His nineteen years of clinical investigation has been performed at Paradise Valley Hospital and Sharp Chula Vista Medical Center. As Principal Investigator, he has directed over 70 studies including cSSSI, Stroke, Acute Myocardial Infarction, Unstable Angina, Sepsis, Septic Shock, Hospital & Community Acquired Pneumonia, Hepatitis C, Atrial Fibrillation, Congestive Heart Failure, Hyponatremia, Complicated Appendicitis, UTI/Pyleonephritis, Occluded Central Venous Access Devices, genomic studies and more. He has served as Chief of Staff at Paradise Valley Hospital and President of the American College of Emergency Physicians in California. Dr. O’Riordan has also served on numerous advisory adjudication committees including AstraZeneca, Basilea Pharmaceutica, Aventis Pharmaceuticals, Inc., Hoechst Marion Roussel among others. He is an examiner for the American Board of Emergency Medicine and a Fellow of the American College of Emergency Physicians. Dr. O’Riordan earned his medical degree from the University of Kansas Medical School and is licensed in Kansas and California.